The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-25. Anything still debated is marked as such rather than presented as settled.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
=== Endoscopy === After Edlich learned about endoscopes in Asia, he received an endoscope for gastroscopic visualization of the patient's stomach. As a surgical resident, Edlich was the first physician to do a gastroscopy at the University of Minnesota Medical Center. Edlich's picture was featured on the cover of Postgraduate Medicine, the Journal of Applied Medicine, in November 1968. His experiences with gastroscopy led to the first minimally invasive surgical procedure at the University of Minnesota Hospital, an endoscopic gastrostomy. Edlich soon realized the limitations of the thick, narrow-diameter latex Ewald tubes that were being used to evacuate blood clots from the patient's stomach before endoscopic examination. Edlich devised a thin-walled, transparent, plastic tube for evacuation of blood clots from a patient's stomach.
The steroidogenic acute regulatory protein, commonly referred to as StAR (STARD1), is a transport protein that regulates cholesterol transfer within the mitochondria, which is the rate-limiting step in the production of steroid hormones. It is primarily present in steroid-producing cells, including theca cells and luteal cells in the ovary, Leydig cells in the testis and cell types in the adrenal cortex.
=== Lifestyle and drug management === Kalra has consistently emphasised the importance of lifestyle interventions in obesity management. He has highlighted the use of traditional and indigenous activities to improve physical function in people living with obesity. He has also worked extensively on nutrition education and research. Kalra has advocated for the recognition of "mega-nutrients" such as fibre and water, which are consumed in significantly larger quantities than macronutrients. He is also a co-author of the national consensus statement on fibre intake in India. Person-centred obesity care is another major focus of his work. His publications emphasise that obesity management requires individualised strategies rather than a uniform approach. Kalra has remained closely engaged with developments in GLP-1 receptor agonists and has published periodic updates as new evidence has emerged.
== Journals == Numerous journals are dedicated to the field of proteomics and related areas. Note that journals dealing with proteins are usually more focused on structure and function while proteomics journals are more focused on the large-scale analysis of whole proteomes or at least large sets of proteins. Some relevant proteomics journals are listed below (with their publishers).
===== Domestic electrical installation ===== Ground fault interrupters are available to reduce electric fields and (in the case of current flow) magnetic fields from residential electrical installations. In plaster installations, only a small part of the electric field can escape from the wall. However, a mains disconnect switch automatically disconnects the relevant line as long as no electrical load is switched on; as soon as a load is switched on, the mains voltage is also switched on. Ground fault interrupters were introduced in 1973 and have been continuously improved over the decades. In 1990, for example, it became possible to disconnect the PEN conductor (formerly known as the neutral conductor). Circuit breakers can be installed in several different circuits, preferably in those that supply bedrooms. However, they only turn off when no continuous current consumers such as air conditioners, fans, humidifiers, electric alarm clocks, night lights, standby devices, alarm systems, chargers, and similar devices are turned on. Instead of the mains voltage, a low voltage (2-12 volts) is applied, which can be used to detect when a consumer is switched on. Rooms can also be shielded with copper wallpaper or special wall paints containing metal, thus applying the Faraday cage principle.
Sources: en.wikipedia.org
Corticotropic cells, (corticotropes or corticotrophs) are basophilic cells in the anterior pituitary that produce pro-opiomelanocortin (POMC) which undergoes cleavage to adrenocorticotropin (ACTH), β-lipotropin (β-LPH), and melanocyte-stimulating hormone (MSH). These cells are stimulated by corticotropin releasing hormone (CRH) and make up 15–20% of the cells in the anterior pituitary. The release of ACTH from the corticotropic cells is controlled by CRH, which is formed in the cell bodies of parvocellular neurosecretory cells within the paraventricular nucleus of the hypothalamus and passes to the corticotropes in the anterior pituitary via the hypophyseal portal system. Adrenocorticotropin hormone stimulates the adrenal cortex to release glucocorticoids and plays an important role in the stress response.
=== Polymorphisms === Single nucleotide polymorphisms (SNPs) genetic variations within OPRK1, have been associated with susceptibility to substance use disorders and stress-related behaviors. The G36T SNP (rs1051660) is more frequent in heroin-dependent individuals compared to healthy controls. Other study found an association of OPRK1 variants with cocaine dependence and relapse susceptibility.
ACAM2000 is a smallpox vaccine manufactured by Emergent Biosolutions. It provides protection against smallpox for people determined to be at high risk for smallpox infection. ACAM2000 is a live replicating vaccinia virus vaccine. Like other smallpox vaccines, it also works as a vaccine for mpox and was approved for this purpose in 2024.
=== Industrial hazards === Sulfuric acid is non-flammable. The main occupational risks posed by this acid are skin contact leading to burns (see above) and the inhalation of aerosols. Exposure to aerosols at high concentrations leads to immediate and severe irritation of the eyes, respiratory tract and mucous membranes: this ceases rapidly after exposure, although there is a risk of subsequent pulmonary edema if tissue damage has been more severe. At lower concentrations, the most commonly reported symptom of chronic exposure to sulfuric acid aerosols is erosion of the teeth, found in virtually all studies: indications of possible chronic damage to the respiratory tract are inconclusive as of 1997. Repeated occupational exposure to sulfuric acid mists may increase the chance of lung cancer by up to 64 percent. In the United States, the permissible exposure limit (PEL) for sulfuric acid is fixed at 1 mg/m3: limits in other countries are similar. There have been reports of sulfuric acid ingestion leading to vitamin B12 deficiency with subacute combined degeneration. The spinal cord is most often affected in such cases, but the optic nerves may show demyelination, loss of axons and gliosis.
Sources: en.wikipedia.org
nickase Another name for a nicking enzyme, especially one that has been artificially engineered to create single-stranded breaks (i.e. nicks) by altering the cleavage activity of an endonuclease that normally creates double-stranded breaks, e.g. Cas9 nickase (nCas9).
=== Pharmacodynamics === Flupirtine is a selective neuronal KCNQ (Kv7) potassium channel opener. This action is thought to be primarily responsible for its effects. The drug may also act as a GABAA receptor positive allosteric modulator and this action may be involved in its muscle relaxant effects. The drug was long thought to act as an NMDA receptor antagonist, but it does not directly interact with NMDA receptors. Instead, it has been elucidated that flupirtine indirectly inhibits NMDA receptors by opening KCNQ potassium channels. As such, the drug has since been described as an indirect or "functional" NMDA receptor antagonist. Flupirtine was the first KCNQ potassium channel opener to be introduced for medical use.
Human bonding is the process of development of a close interpersonal relationship between two or more people. It most commonly takes place between family members or friends, but can also develop among groups, such as sporting teams and whenever people spend time together. Bonding is a mutual, interactive process, and is different from simple liking. It is the process of nurturing social connection. Bonding typically refers to the process of attachment that develops between romantic or platonic partners, close friends, or parents and children. This bond is characterised by emotions such as affection and trust. Any two people who spend time together may form a bond. Male bonding refers to the establishment of relationships between men through shared activities. The term female bonding refers to the formation of close personal relationships between women. Cross-sex friendships refers to personal relationships between men and women.
== Evolving organizational linkages with the State Department == Foreign aid has always operated within the framework of U.S. foreign policy and the organizational linkages between the Department of State and USAID have been reviewed on many occasions. In 1978, legislation drafted at the request of Senator Hubert Humphrey was introduced to create a Cabinet-level International Development Cooperation Agency (IDCA), whose intended role was to supervise USAID in place of the State Department. Established by executive order in September 1979, it did not in practice make USAID independent. In 1995, legislation to abolish USAID was introduced by Senator Jesse Helms, the chairman of the Senate Foreign Relations Committee, who aimed to replace USAID with a grant-making foundation. Although the House of Representatives passed a bill abolishing USAID, the measure did not become law. To gain congressional cooperation for his foreign affairs agenda, President Bill Clinton adopted in 1997 a State Department proposal to integrate more foreign affairs agencies into the department. The "Foreign Affairs Agencies Consolidation Act of 1998" (Division G of PL 105-277) abolished IDCA, the Arms Control and Disarmament Agency, and the United States Information Agency, which formerly maintained American libraries overseas. Although the law authorized the president to abolish USAID, President Clinton did not exercise this option.
== Chemistry == Dihydroergocryptine is a mixture of two very similar compounds, alpha- and beta-dihydroergocryptine (epicriptine) at a ratio of 2:1. The beta differs from the alpha form only in the position of a single methyl group, which is a consequence of the biosynthesis of the parent compound ergocryptine, in which the proteinogenic amino acid leucine is replaced by isoleucine. Dihydroergocryptine is a hydrogenated ergot derivative that is also structurally very similar to bromocriptine, another drug that has anti-Parkinson effects. DHEC differs in that it is hydrogenated in C9–C10 and lacks bromine in C2. In fact, all ergot derivatives are uniquely or mainly D2-like receptor agonists.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.